Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Povetacicept in Adults with Generalized Myasthenia Gravis
2025-523950-15-01Phase 2Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing Povetacicept with Placebo (2 arms). Primary endpoints: Percent change in total immunoglobulin G (IgG) and Safety and tolerability (AEs and SAEs). Planned start May 2026; status: authorised.
02
Drugs
povetacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-523950-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523950-15-01.